Case Study: BioInteractions Ltd
BioInteractions Ltd is a research and development company specialising in biomaterial technologies for the worldwide medical device industry. Based in purpose built laboratories in the Science and Technology Centre at the University of Reading, the company develops advanced and specialised coatings for devices used in medical treatments and procedures such as instruments and implants. With their biocompatible technology BioInteractions aims to improve the well-being of patients and increase recovery times thereby also providing benefits for clinicians and health services.
BioInteractions have secured licensing contracts with major medical device manufacturers around the world and in 2002 won the Queen's Award for Enterprise for a biocompatible coating that was the first to combine multiple elements for total biocompatibility in just one coating.
BioInteractions develop novel biocompatible biodegradable biomaterials for medical devices such as drug eluting stents. A drug eluting stent is a coronary stent - like scaffolding - which is placed in a narrowed or diseased artery to keep the artery open. The stent slowly releases a drug that blocks cell replacement preventing cell regrowth, the stent imbedding itself and reblocking the artery, a process called restenosis.
BioInteractions were seeking to develop a chemical material which was biocompatible and could be applied to coatings of medical devices - like drug eluting stents - that the human body would not reject or respond to.
BioInteractions were seeking to design and develop novel biocompatible biodegradable biomaterials for medical devices such as drug eluting stents. Dr John McKendrick, Lecturer in Organic Chemistry at the University of Reading, acted as the academic supervisor on the KTP for the Associate.
The Associate utilised prior knowledge of polymer chemistry, making blends and experimenting with biocompatible materials and polymers to develop different blends that resulted in the creation of a new family of biodegradable and biostable biomaterials. This included the development of a new antiproliferative agent to prevent restenosis.
Benefits to BioInteractions LTD
The terms of the KTP allow BioInteractions to retain Intellectual Property (IP) created during the partnership. Three patents have been filed and registered in the US and Europe, leading to licensing opportunities for the company, which, as well as generating income, will expand its operations in the area of biomaterials.
In addition the project has expanded BioInteractions' knowledge and expertise in organic chemistry as well as its application in biomaterials for medical devices.
Benefits to the Associate
As a result of the success of the KTP project the Associate was employed by the company as a Research Scientist, and is now (October 2009) acting as the Industrial Supervisor on a second KTP for BioInteractions.
Through the novel material created in the course of the KTP and the support from the University and BioInteractions the Associate was able to gain his PhD qualification.
“The KTP has enabled us to develop new and innovative technologies, which have enhanced our product portfolio and increased the potential for new licensing opportunities.”